STOCK TITAN
  1. Home
  2. BCYP

BCYP Stock Price, News & Analysis

BCYP NASDAQ

Company Description

BCYP (NASDAQ: BCYP) is a publicly traded company.

BCYP stock has declined 16.9% over the past year.

This page provides a comprehensive overview of BCYP stock, including real-time price data, latest news, SEC filings, insider trading activity, financial highlights, upcoming events, and short interest trends.

Stock Performance

Chart
$—
0.00%
0.00
Last updated:
-16.85%
Performance 1 year
$0.0
Market Cap
14.8M
Shares outstanding

BCYP (BCYP) stock. Over the past 12 months, the stock has lost 16.9%.

Latest News

View All
+5.24%

Big Cypress Acquisition Corp. Stockholders Approve Business Combination with SAB Biotherapeutics

acquisition
-0.05%

SAB Biotherapeutics to Host Virtual R&D Day on October 13, 2021

conferences
0.00%

SAB Biotherapeutics Announces First Patient Dosed in Phase 3 NIH ACTIV-2 Trial Evaluating SAB-185 for Treatment of COVID-19

clinical trial covid-19
+0.10%

SAB Biotherapeutics Appoints Russell Beyer Chief Financial Officer

management
0.00%

SAB Biotherapeutics Announces SAB-185 Receives Positive DSMB Review and Advances to Phase 3 in NIH-Sponsored ACTIV-2 Trial for Treatment of COVID-19

clinical trial covid-19
+0.29%

Big Cypress Acquisition Corp Announces Special Meeting of Stockholders to Approve Business Combination with SAB Biotherapeutics

acquisition

BCYP has 10 recent news articles. Of the recent coverage, 4 articles coincided with positive price movement and 1 with negative movement. Key topics include acquisition, conferences, clinical trial, covid-19, management. View all BCYP news →

SEC Filings

View All

No SEC filings available for BCYP.

Financial Highlights

View Full Financials
—
Revenue (TTM)
—
Net Income (TTM)
—
Diluted EPS (TTM)
—
Operating Cash Flow
—
Net Profit Margin
—
Oper. Profit Margin

Upcoming Events

Short Interest History

Last 12 Months

Days to Cover History

Last 12 Months